Back to search results

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Abroad (travel likely)TerminatedPHASE2

Conditions

Acute Ischemic Stroke

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Investigational site 13, Aichi, Japan

  • Investigational site 39, Aomori, Japan

  • Investigational site 19, Chiba, Japan

  • Investigational site 28, Chiba, Japan

  • Investigational site 33, Ehime, Japan

  • Investigational site 10, Fukui, Japan

  • Investigational site 05, Fukuoka, Japan

  • Investigational site 09, Fukuoka, Japan

  • Investigational site 11, Fukuoka, Japan

  • Investigational site 12, Fukuoka, Japan

  • Investigational site 18, Fukuoka, Japan

  • Investigational site 21, Fukuoka, Japan

  • Investigational site 32, Fukuoka, Japan

  • Investigational site 37, Fukuoka, Japan

  • Investigational site 07, Fukushima, Japan

  • Investigational site 08, Fukushima, Japan

  • Investigational site 15, Gifu, Japan

  • Investigational site 23, Gifu, Japan

  • Investigational site 02, Gunma, Japan

  • Investigational site 01, Hokkaido, Japan

  • Investigational site 22, Hokkaido, Japan

  • Investigational site 06, Hyōgo, Japan

  • Investigational site 30, Hyōgo, Japan

  • Investigational site 42, Hyōgo, Japan

  • Investigational site 43, Ishikawa, Japan

  • Investigational site 40, Kanagawa, Japan

  • Investigational site 24, Kochi, Japan

  • Investigational site 35, Miyagi, Japan

  • Investigational site 16, Nagano, Japan

  • Investigational site 20, Nagano, Japan

  • Investigational site 27, Numakunai, Japan

  • Investigational site 44, Okayama, Japan

  • Investigational site 41, Okinawa, Japan

  • Investigational site 03, Osaka, Japan

  • Investigational site 25, Osaka, Japan

  • Investigational site 38, Saga, Japan

  • Investigational site 31, Saitama, Japan

  • Investigational site 14, Shimane, Japan

  • Investigational site 29, Tochigi, Japan

  • Investigational site 36, Tochigi, Japan

  • Investigational site 17, Tokyo, Japan

  • Investigational site 45, Tokyo, Japan

  • Investigational site 34, Yamagata, Japan

  • Investigational site 04, Yamaguchi, Japan

  • Investigational site 26, Yamaguchi, Japan

Study leads

  • General Manager

    Study Director

    Tanabe Pharma Corporation

View source on ClinicalTrials.gov(opens in a new tab)

No study contact email or phone is listed for this trial.